Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | RGS12 | O14924 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | FPR2 | P25090 | 1/20 | 0.30 |
| ▸ | COMT | P21964 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17995108 | 0.77 | — | — | |
| SCHEMBL8303900 | 0.72 | MAPT (0.36) | KMT2AMEN1MAPTRGS12USP2 | |
| SCHEMBL16660226 | 0.69 | ALDH1A1 (0.35) | ALDH1A1POLB | |
| SCHEMBL16660150 | 0.69 | MYC (0.37) | MAPT | |
| SCHEMBL16660209 | 0.67 | — | — | |
| SCHEMBL15337415 | 0.67 | DAO (0.32) | — | |
| SCHEMBL15337636 | 0.67 | HSD17B10 (0.47) | MAPTUSP2ALDH1A1GAAHTT | |
| SCHEMBL16659852 | 0.67 | AXL (0.33) | — | |
| SCHEMBL16425569 | 0.67 | OPRM1 (0.42) | KMT2AMEN1ALDH1A1HTT | |
| SCHEMBL17708125 | 0.66 | NR1I2 (0.35) | KMT2AMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10077254-B2 | Tetrazolinone compound and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2018-09-18 | — | — | US | disclosed |
| EP-3059233-B1 | TETRAZOLINONE COMPOUND AND APPLICATION FOR SAME | SUMITOMO CHEMICAL CO (JP) | 2017-12-20 | — | — | EP | disclosed |
| EP-3059233-B1 | TETRAZOLINONE COMPOUND AND APPLICATION FOR SAME | SUMITOMO CHEMICAL CO (JP) | 2017-12-20 | — | — | EP | disclosed |
| US-20160272622-A1 | TETRAZOLINONE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-09-22 | — | — | US | disclosed |
| EP-3059233-A1 | TETRAZOLINONE COMPOUND AND APPLICATION FOR SAME | Sumitomo Chemical Company, Limited (JP) | 2016-08-24 | — | — | EP | disclosed |
| EP-3059233-A1 | TETRAZOLINONE COMPOUND AND APPLICATION FOR SAME | Sumitomo Chemical Company, Limited (JP) | 2016-08-24 | — | — | EP | disclosed |
| WO-2015056811-A1 | TETRAZOLINONE COMPOUND AND APPLICATION FOR SAME | 住友化学株式会社 | 2015-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10077254-B2 | Tetrazolinone compound and use thereof | MT-CO1, UQCRB, MT-CO2 | KMT2A 3167/4885MEN1 2402/4885MAPT 3682/4885 |
| US-20160272622-A1 | TETRAZOLINONE COMPOUND AND USE THEREOF | MT-CO1, UQCRB, MT-CO2 | KMT2A 3167/4885MEN1 2402/4885MAPT 3682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.